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Abstract:  26 
Selenomethionine is an essential amino acid with a narrow therapeutic index and 27 
susceptibility to oxidation. Here it was encapsulated into a nanoparticle composed of chitosan 28 
cross-linked with tripolyphosphate for oral delivery. The formulation was optimised using a 29 
three-factor Box-Behnken experimental design. The chitosan:tripolyphosphate ratio, chitosan 30 
solvent pH, and drug load concentration were independently varied. The dependent variables 31 
studied were encapsulation efficiency, particle size, polydispersity index and zeta potential. 32 
For optimisation, encapsulation efficiency and zeta potential were maximised, particle 33 
diameter was set to 300 nm and polydispersity index was minimised. A 0.15mg/mL 34 
concentration of selenomethionine, chitosan solvent pH of 3, and chitosan:tripolyphosphate 35 
ratio of 6:1 yielded optimum nanoparticles of size 187±58nm, polydispersity index 36 
0.24±0.01, zeta potential 36±6mV, and encapsulation efficiency of 39±3%. Encapsulation 37 
efficiency was doubled to 80±1.5% by varying pH of the ionotropic solution components and 38 
by subsequent coating of the NPs with zein, increasing NP diameter to 377±47nm, whilst 39 
retaining polydispersity index and zeta potential values. Selenomethionine-entrapped 40 
nanoparticles were not cytotoxic to intestinal and liver cell lines. Accelerated thermal 41 
stability studies indicated good stability of the nanoparticles under normal storage conditions 42 
(23°C). In simulated gastrointestinal and intestinal fluid conditions, 60% cumulative release 43 
was obtained over 6 hours.  44 
 45 
 46 
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 48 
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Abbreviations 53 
BBD, Box-Behnken design; CL113, PROTASAN™ UP; Cs, Chitosan; DLS, dynamic light 54 
scattering; EE%, Encapsulation efficiency; GRAS, Generally recognised as safe; LDV, laser 55 
doppler velocimetry; MSC, methylselenocysteine; NP, nanoparticle; PDI, Polydispersity; pI, 56 
Isoelectric point; SeCys, selenocysteine; SeMet, Selenomethionine; TPP, Tripolyphosphate; 57 
ZP, Zeta potential.  58 
1 INTRODUCTION 59 
Selenium is an essential micronutrient in human and animal nutrition (Rayman, 2000), that 60 
exists in a wide array of different formats, both organic and inorganic, better known as 61 
speciation. Selenomethionine (SeMet), the selenium analogue of  methionine, is the 62 
predominant form of organic Se found in foods from the Brassica and Allium families (Reilly 63 
et al., 2014). SeMet is used for oral supplementation due to its capacity to be non-specifically 64 
incorporated into body proteins in place of methionine (Rayman et al., 2008). The potential 65 
health benefits of selenium are dependent on its chemical species, and several studies have 66 
suggested a possible role in cancer prevention (Nie et al., 2016), increased immunological 67 
status (Narayan et al., 2015) and increased fertility (Shanmugam et al., 2015). SeMet may 68 
also to have a number of benefits regarding oncology treatments due to its modulation of the 69 
therapeutic efficacy and selectivity of anticancer drugs (Evans et al., 2017), capacity to 70 
provide protection of normal tissues from the toxicities associated with chemotherapy and 71 
radiation treatments, in addition to enhancing their anti-tumour effects (Chintala et al., 2012; 72 
Mix et al., 2015; Panchuk et al., 2016). It may also have some potential in degenerative 73 
disease by decreasing oxidative stress of small molecule antioxidants used as a buffer for free 74 
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radicals in brain tissue (Reddy et al., 2017; Song et al., 2014). However, the oral delivery of 75 
SeMet can be challenging due to the distinctive electronegativity and atomic radius of the 76 
selenium atom (i.e. larger radius and lower electronegativity than sulphur,) that makes it 77 
easier for low valence state Se compounds to be more readily oxidised compared to their 78 
sulphur counter parts (Xu et al., 2013). SeMet is readily oxidised (Davies, 2016) and, even 79 
though it is less toxic than inorganic selenium (Se), it still has a low therapeutic index 80 
(Takahashi et al., 2017). Oral delivery formulations of SeMet therefore need to consider the 81 
balance between doses that exert beneficial effects and those which may potentially be toxic.  82 
 83 
Inorganic Se species such as selenite (SeO32-) and elemental selenium (Se0), together with 84 
methylseleninic acid, have been formulated to nano-enabled delivery systems which 85 
exhibited improved bioactivity with reduced cytotoxicity in vitro (Forootanfar et al., 2014; 86 
Loeschner et al., 2014; Zhang et al., 2008). Nanoparticles (NPs) can be more biologically 87 
active due to their enhanced surface area per mass compared with larger-sized particles of the 88 
same chemistry (Oberdörster et al., 2005). By using NPs as a drug delivery vehicle, it might  89 
be possible to enhance a range of characteristics for a given bioactive, including; increased 90 
protection and stability (Nair et al., 2010) and suitability to increase bioavailability by non-91 
parenteral routes of administration including oral, pulmonary and topical applications 92 
(Helson, 2013). 93 
 94 
The natural polymer chitosan (Cs) is a mucopolysaccharide, closely related to cellulose and 95 
obtained by deacetylation of the compound chitin, predominantly found in the exoskeletons 96 
of crustaceans (Nagpal et al., 2010). Cs has been used for the development and formulation of 97 
nanoparticles by ionotropic gelation due to its physicochemical and biological beneficial 98 
properties (Mohammed et al., 2017; H. Zhang et al., 2015). Benefits include improved 99 
5 
 
adherence to mucosal surfaces, increased drug residence time (Ryan et al., 2012),  and 100 
protection of the bioactive drug from intestinal proteases (Amaro et al., 2015; Ryan et al., 101 
2013). In acidic medium, Cs can be dissolved, due to protonation of the amine residues 102 
present in the polymer backbone. Ionotropic gelation allows for the formation of NPs from 103 
Cs via crosslinking with oppositely-charged electrolytes under mild conditions in which 104 
amino acids and peptides will remain reasonably stable (Chen et al., 2013; Janes et al., 2001; 105 
Wang et al., 2011). 106 
 107 
Zein a GRAS approved prolamine-rich protein derived from maize, has been used in the 108 
formulation and coating of peptide oral delivery systems (Y. Zhang et al., 2015), to increase 109 
encapsulation efficiency (Luo and Wang, 2014) and improve the control of gastric release of 110 
labile bioactives (Luo et al., 2010; Paliwal and Palakurthi, 2014).  By exploiting the physical 111 
interactions between protein and polysaccharide (in this instance zein and Cs), it is possible 112 
to improve and broaden the physical and chemical stability properties of the NP delivery 113 
systems (Benshitrit et al., 2012). However, the formulation, characterisation and development 114 
of these multi-component systems can be more challenging than single component systems 115 
and as such, it is important to comprehensively optimise the formulation process.  To the best 116 
of our knowledge, there are currently no reports which describe the formulation of biological 117 
Se species such as SeMet into a NP delivery system. The potential optimisation of this 118 
formulation could be significant, given that SeMet more effectively increases human and 119 
animal selenium levels and is less toxic than inorganic Se (Garousi, 2015). 120 
 121 
In situations where several variables may influence system properties, a useful technique to 122 
identify the relationships between a given response and independent variables (or factors) and 123 
optimise the system, is Response Surface Methodology (RSM) (Anderson and Whitcomb, 124 
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2005). RSM is a more efficient approach to experimentation than one factor at a time (OFAT) 125 
experiments since it: 1) reduces the number of experimental runs typically required to gather 126 
the same information as OFAT, thus reducing resource requirements, 2) is useful in detecting 127 
interdependencies of variables that would not be typically identified during OFAT 128 
experiments and 3) improves the prediction of a response through use of gathered 129 
information from a larger parameter space. One of the most commonly applied RSM designs 130 
for process optimisation with a minimal experimental requirement is the Box-Benhken design 131 
(BBD), an independent quadratic design in which factor combinations are considered at 3 132 
levels; the midpoints of edges of the process space and the centre (Traynor et al., 2013; 133 
Zolgharnein et al., 2013). After polynomial models for each of the different responses in a 134 
study have been completed, a desirability function may be constructed in order to estimate 135 
minima or maxima, provided such optima are within the design space (Bezerra et al., 2008).  136 
 137 
In this study, SeMet was formulated into nanoparticles consisting of Cs and zein using 138 
ionotropic gelation. After evaluating the main variables which affect encapsulation 139 
efficiency, particle size and drug loading, a systematic approach (RSM) was used to optimise 140 
the formulation of nanoparticles suitable for oral delivery. A three-level, three-factor BBD 141 
was utilised to build polynomial models for the three responses and a desirability function 142 
was then constructed to optimise the system. Optimised SeMet NPs were prepared based on 143 
the predicted optimum levels of the independent variables of the factorial design. To ensure 144 
stability of the optimised formulation after lyophilisation, a cryoprotectant (trehalose) was 145 
also included (Danish et al., 2017a). The physicochemical properties, storage stability, 146 
cytotoxicity, and the release profile in a simulated intestinal buffer were assessed.  147 
2 MATERIALS AND METHODS  148 
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2.1 Materials 149 
The chitosan ultrapure PROTASAN™ UP (CL113, Mw=110-150kDa, DDA=85%, 150 
Endotoxins ≤ 100 EU/gram, Heavy metals≤ 40 ppm) was purchased from NovaMatrix, FMC 151 
Corporations, Norway. DL-selenomethionine, D(+)-Trehalose dihydrate, and zein, of  ≥99% 152 
purity, were obtained from ACROS Organics™, Fisher Scientific, Ireland. Ultra-pure water 153 
18mΩcm-1 was obtained from a Millipore simplicity 185 model instrument, UK, and was 154 
used for all aqueous solution preparations throughout. Sodium Tripolyphosphate (TPP) of 155 
technical grade (85%), and all other reagents, chemicals and solvents were of analytical grade 156 
from Sigma Aldrich, Ireland.  157 
2.2  Optimisation of nanoparticle formulation physicochemical properties 158 
A BBD was used to optimise the formulation and EE% of SeMet into the nanoparticle. 159 
Selected target physicochemical properties for oral delivery for the NPs were particle size of 160 
approximately 300 nm, PDI < 0.5 and ZP > 30 mV (des Rieux et al., 2006). A three level, 161 
three factor BBD (Maleki Dizaj et al., 2015; Zhao et al., 2013) of 15 random order 162 
experiments was designed using Minitab™ 17 (Pennsylvania, USA). The 3 independent 163 
variables were, (X1) the pH of the Cs solvent - the isoelectric point (pI) of SeMet, (pH-pI) 164 
(X2), the load concentration of SeMet and (X3) the ratio of Cs:TPP, while (Y1) Particle size, 165 
(Y2) PDI, (Y3) ZP  and (Y4) EE% were the dependent variables. The variable ranges (Table 166 
1) were based on an exploratory study.  167 
Each dependant variable was independently assessed by linear regression using a 2nd degree 168 
polynomial model with 1st order interactions (Eq. 1). 169 
 170 
Yi = b0 + b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3 + b23X2X3 + b11X12 + b22X22 + b33X32+ε 171 
            (Eq. 1) 172 
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where Yi is the measure of the response associated with each factor level combination, b0 is 173 
an intercept, b1-b33 are the regression coefficients, X1-X3 are the coded independent variables 174 
and the XiXj and Xi2 (i,j = 1, 2, 3) denote the interactive and quadratic terms, respectively. The 175 
linear regression and the significance (p<0.05) test of independent variables and their 176 
interactions was assessed by statistical software (Minitab™,17) to generate regression 177 
models. Through bidirectional elimination (testing at each step for variables to be included or 178 
excluded), non-significant terms were removed from the model in order to calculate 179 
regression equations with significant terms only (Wang et al., 2013).  Desirability functions 180 
to optimise all responses were built the weighted geometric mean of individual desirabilities 181 
presented in Table 1. 182 
 183 
Table 1: Variables and levels employed in the BBD with desirability function for 184 
optimisation of nanoparticle formulation.  185 
 
Factor (Independent variables) 
 
       Levels used, (Actual coded) 
X1 = pH of the Cs solvent – the pI of SeMet (pH- pI) 0.5 1.5 2.5 
X2 = SeMet concentration (mg/mL) 0.05 0.15 0.25 
X3 = ratio of Cs:TPP 4:1 6:1 8:1 
Dependent Variables Composite desirability 
Y1= Size (nm) Target of 300nm 
Y2 = PDI Minimise 
Y3 = ZP (mV) Maximise 
Y4 = Encapsulation efficiency (EE%) Maximise 
 186 
Response surface plots, statistical testing of the linear models and identification of optimum 187 
formulations via feasibility and grid searches was performed to study the optimal area 188 
(Barrentine, 1999). Finally, repetitions (N=4) of the optimal point found were conducted 189 
experimentally to validate the study. 190 
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2.3 Preparation of SeMet loaded Cs:TPP nanoparticles  191 
SeMet-entrapped NPs were produced using a modified ionic gelation method (Calvo et al., 192 
1997). Briefly, Cs was dissolved in buffered pH medium (3, 4 or 5 pH) at a concentration of 193 
3 mg/mL and filtered through a 0.22 μm syringe filter (Millex Millipore, UK) to remove 194 
undissolved Cs. A known amount of SeMet was then added to the Cs solution prior to 195 
crosslinking to obtain a final load concentration 0.05, 0.150 or 0.250 mg/mL. TPP was added 196 
dropwise to the solution under stirring at 700 rpm and room temperature to yield final mass 197 
ratios of Cs:TPP NPs of 4:1, 6:1 and 8:1. All of these experimental parameters (pH, 198 
concentrations and ratios) were prepared according to the BBD design. The NP suspension 199 
was stirred at 700 rpm for 30 min at room temperature for further crosslinking. After 200 
stabilisation, NPs were then transferred to a 30 kDa molecular weight cut off (Vivaspin 20, 201 
Sartorius) centrifugal filter and isolated by centrifugation at 3000 rpm for 30 min. Filtered 202 
H2O (equivalent in volume to the recovered supernatant) was then added to the isolated NPs 203 
and sonicated at 35 % amplitude for 30 s with 5 s pulse intervals. Physicochemical properties 204 
of the NPs were then determined as per section 2.4, using a Malvern Zetasizer NanoZS 205 
(Worcestershire, UK) and the supernatant was retained for EE% determination as outlined in 206 
section 2.7. The optimised formulation has a mass ratio 6:1 (Cs:TPP), Cs media (pH 5), and a 207 
final SeMet load concentration of 0.15 mg/mL.  208 
2.3.1 Increase of Ionisation/Protonation states of NP components during ionic gelation to 209 
increase EE% - Formulation I 210 
After optimising the general physicochemical properties via BBD (section 2.2), the ionic 211 
gelation component preparation procedure was modified with the aim of increasing the EE %. 212 
Formulation I was produced as described in section 2.3 with one exception; SeMet and TPP 213 
were dissolved and diluted with NaOH (0.01 M) prior to crosslinking. The rationale for the 214 
pH adjustment was to induce higher electrostatic interactions (i.e. maximise the cationic 215 
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component of Cs and the anionic component of SeMet) between SeMet and Cs during the 216 
crosslinking process. 217 
2.3.2 Coating NPs with zein to increase EE% 218 
NPs were prepared as per formulation I (ratio 6:1 (Cs:TPP), Cs media (pH 3), TPP/SeMet 219 
NaOH solution (pH 11) and a final load concentration of 0.15 mg/mL), with the following 220 
modifications; after the NPs had stabilised, 8 mL of absolute EtOH were added dropwise to 221 
the formulation whilst the stirring speed of the solution was maintained at 700 rpm for 30 min 222 
at room temperature. Zein (10 mg/mL dissolved in 80 % EtOH and filtered) was added 223 
dropwise to yield zein:Cs mass ratios of 0.5:1, 1:1 and 2:1, stabilised at 700 rpm for 30 min 224 
and isolated as per section 2.3. The NP formulations were then concentrated under vacuum 225 
(175 mbar) at 40 °C until EtOH was completely removed. To ensure stability of the 226 
optimised formulation after lyophilisation, 10 mL of the cryoprotectant trehalose 5 % w/v in 227 
H2O was added to each formulation and lyophilised for 36 hr (Danish et al., 2017a).  228 
 229 
2.4 Nanoparticle Characterisation: Particle size, PDI and surface charge 230 
Freshly prepared NP solutions were used for physicochemical analysis (Luo et al., 2010). The 231 
mean particle size and PDI of the NP formulations were determined by dynamic light 232 
scattering (DLS). The ZP values were measured with the use of laser doppler velocimetry 233 
(LDV). Both DLS and LDV analysis were performed in triplicate at 25 °C with a Zetasizer 234 
Nano series Nano-ZS ZEN3600 fitted with a 633 nm laser (Malvern Instruments Ltd., UK), 235 
using a folded capillary cuvette (Folded capillary cell-DTS1060, Malvern, UK). The values 236 
presented herein were acquired from three separate experiments, each of which included 237 
three replicates; N=3. 238 
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2.5 Scanning electron microscopy (SEM) 239 
NP morphology was evaluated by scanning electron microscopy (SEM) (Hitachi, SU6600 240 
FESEM, USA), at an accelerating voltage of 20 kV, unless otherwise stated, using the 241 
secondary electron detector. The fresh NP solutions were then spin coated onto Si wafers, 242 
dried at room temperature and then sputter coated with 4 nm Au/Pd prior to imaging 243 
(Mukhopadhyay et al., 2013).  244 
2.6 Fourier transform infrared spectroscopy (FTIR) 245 
FTIR spectra of CL113, TPP, Cs:TPP NPs, SeMet and SeMet loaded Cs:TPP NPs were 246 
acquired via a Spotlight 400 series spectrometer (Perkin Elmer, USA), using the attenuated 247 
total reflectance spectroscopy method (ATR-FTIR), in the range of 650-4000 cm-1. Prior to 248 
analysis, NP samples were lyophilised using a FreeZone 6 L bench top freeze dry system 249 
(Labconco, USA) at -40 °C for 20 hr. The dried solids were then placed on the ATR crystal 250 
prism (ZnSe), and 32 scans were acquired at 4 cm−1 resolution with background subtraction 251 
using the empty sample holder (Vongchan et al., 2011).  252 
2.7 EE% of SeMet in Cs:TPP nanoparticles 253 
The EE% of SeMet in the NPs was determined by the separation and quantification of SeMet 254 
left in the supernatant. This was performed by ultracentrifugation at 3000 rpm, 4 °C for 30 255 
min. SeMet in the supernatant was quantified by reverse phase high performance liquid 256 
chromatography (RP-HPLC), as previously described (Ward et al., 2012) with the following 257 
modifications. Samples were analysed with a Waters 2998 HPLC and Photodiode Array 258 
Detector, (Waters, USA), using a Poroshell 120, EC-C8 column, 3.0 x 100 mm, 2.7 μm, 259 
(Agilent Technologies, UK). Isocratic elution was carried out at a flow rate of 0.4 mL/min, 260 
column temperature 45.0 ± 5.0 °C with a mobile phase of water/methanol/trifluoroacetic acid 261 
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(97.9:2.0:0.1). Samples were monitored according to their UV absorbance at 218 nm. The 262 
encapsulation efficiency was calculated by Eq. 2 (Xu and Du, 2003); 263 
 264 
 𝑬𝑬% = 𝑻𝑻𝑻𝑻𝑻 𝑻𝒂𝑻𝒂𝒂𝑻 𝑻𝒐 𝑺𝑺 𝑴𝑺𝑻−𝑭𝑭𝑺𝑺 𝑻𝒂𝑻𝒂𝒂𝑻 𝑻𝒐 𝑺𝑺𝑴𝑺𝑻
𝑻𝑻𝑻𝑻𝑻 𝑻𝒂𝑻𝒂𝒂𝑻 𝑻𝒐 𝑺𝑺𝑴𝑺𝑻   X 100 265 
(Eq. 2) 266 
2.8 MTS assay 267 
The potential cytotoxicity of pure SeMet, SeMet loaded NPs and unloaded NPs (coated with 268 
zein) were examined on Caco-2 human epithelial cells, and HepG2 human liver 269 
hepatocellular cells. Both cell lines are routinely employed to assess the potential toxicity of 270 
orally delivered compounds (Brayden et al., 2015; Gleeson et al., 2015). Caco-2 and HepG2 271 
cells, were seeded at a density of 2 x 104 cells/well and cultured on 96 well plates in 272 
Dulbecco's Modified Eagle Medium (DMEM) and Eagle's Minimum Essential Medium 273 
(EMEM) respectively, supplemented with 10 % foetal bovine serum, 1 % L-glutamine, 1 % 274 
penicillin-streptomycin and 1 % non-essential amino acids at 37 °C in a humidified incubator 275 
with 5 % CO2 and 95 % O2. Time points were selected with the intention to mimic in vivo 276 
conditions for each cell type. As the maximum time NPs will be exposed to the intestine, a 4 277 
hr exposure time was used in Caco-2 cell lines (Neves et al., 2016),  to mimic the liver, a 72-278 
h exposure time was used for HepG2 cell lines (Brayden et al., 2014). Triton X-100™ 279 
(0.05%) was used as a positive control. The concentrations of the test compounds applied 280 
were 25, 50 and 100 µM. After exposure, treatments were removed and replaced with MTS 281 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-282 
tetrazolium). Optical density (OD) was measured at 490 nm using a microplate reader 283 
(TECAN GENios, Grodig, Austria). Each value presented was normalised against untreated 284 
control and calculated from three separate experiments, each of which included six replicates.  285 
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2.9 Accelerated stability analysis 286 
NPs were suspended at a concentration of 0.1 mg/mL, in aqueous KCl solution (10 mM) and 287 
stored at accelerated conditions; 60 °C for 720 min, 70 °C for 300 min and 80 °C for 120 min 288 
(Danish et al., 2017b). The particle size, PDI and ZP were measured using the Nanosizer ZS 289 
(Malvern Instruments Ltd, UK) over time intervals to determine the degree of degradation. 290 
The generated data was then analysed via R software (R Core Team, 2016). The temperature 291 
dependence of the kinetic parameters of SeMet-loaded NPs stability was measured by 292 
calculating the observed rate constants. This was plotted in an Arrhenius representation and 293 
apparent activation energy, Ea and reaction rate constant, kref were calculated according to Eq. 294 
3; 295 
𝑷 = 𝑷𝑻 + 𝑺𝑻𝒂 (𝒌)−𝑬𝑻𝑹 (𝟏𝑻− 𝟏𝑻𝑭𝑺𝒐)𝑻 
(Eq.3) 296 
where P is the property (particle size, PDI or ZP) at time t, Po is the initial property 297 
conditions, k is the apparent zero order reaction constant, Ea is the energy of activation, R is 298 
the universal gas constant, T is the temperature of the experiment in Kelvin (K) and Tref is the 299 
reference temperature (343 K).  300 
2.10 In vitro controlled release studies 301 
SeMet release from the NPs was carried out using a dialysis bag diffusion technique 302 
(Hosseinzadeh et al., 2012) over 6 hr (Calderon L. et al., 2013; Yoon et al., 2014). Freeze 303 
dried SeMet loaded NPs were suspended in 5 mL H2O and sonicated at 35 % amplitude for 304 
30 s with 5 s intervals and placed into a Float-A-Lyzer®G2 dialysis membrane with a pore 305 
size of 25 kDa (Spectrum Laboratories, USA). The sample was placed into 40 mL of 306 
simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) specified according to the 307 
British Pharmacopoeia (Pharmacopoeia, 2016). SGF was composed of 0.1 M HCL and SIF 308 
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was composed of 1 volume of 0.2 M trisodium phosphate dodecahydrate and 3 volumes of 309 
0.1 M HCL (adjusted to pH 6.8), without enzymes (British Pharmacopoeia Commission, 310 
2016). Samples were placed in a thermostatic shaker at 37 ºC and agitated at 100 rpm. At 311 
predetermined time points, 1 mL of release fluid was analysed and replaced with simulated 312 
fluid to maintain sink conditions. 313 
 314 
SeMet release was measured by RP-HPLC (section 2.7). Eq. (4) was used to determine the % 315 
drug release; 316 
 317 
𝑫𝑭𝒂𝑫𝑭𝑺𝑻 % = 𝑪(𝑻)𝑪(𝑻) ∗ 𝟏𝟏𝟏 
(Eq. 4) 318 
where 𝐷𝐷𝐷𝐷𝑟𝑟𝑟 is the percentage of SeMet released, C(l) represents the concentration of drug 319 
loaded and C(t) represents the amount of drug released at time t, respectively.  320 
 321 
3 RESULTS AND DISCUSSION 322 
3.1 Response Surface Modelling – Box Behnken design 323 
The observed values for all 15 experiments described by the BBD yielded minimum and 324 
maximum values for Size (Y1) (152, 318 nm), PDI (Y2) (0.218, 0.554), ZP (Y3) (26.0, 42.7 325 
mV) and EE% (Y4) of, (24.7, 41.4 %). The reduced models resulting from the analysis are 326 
presented in table 2. Response Y1 showed no significant terms in the model, suggesting that 327 
there was no evidence in the sample population that could prove the association of the 328 
independent variables with particle size. This finding is unsurprising, as the NPs produced in 329 
this study fell within a narrow target region (152, 318 nm) and the regions of interest chosen 330 
15 
 
in this study (e.g. Cs:TPP 4:1-8:1, pH 3-5), to produce the Cs NPs, have been well 331 
established for yielding  particle sizes within 100-400 nm range (Hassani et al., 2015; 332 
Mohammed et al., 2017; Sipoli et al., 2015). 333 
 334 
Responses Y2-Y4 (PDI, ZP and EE% respectively) all showed a curvature with regards to X1-335 
X3, as quadratic or interactive effects of some independent variables were statistically 336 
significant in all the models.   337 
 338 
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Table 2: Coded variable estimated coefficients (Coef) with associated standard error (SE Coef.) 339 
and uncoded reduced regression equations for Y2-Y4. 340 
Y2 (PDI) Y3 (ZP) Y4 (EE%) 
 
Term 
 
Coef 
 
SE Coef 
 
Term 
 
Coef 
 
SE Coef 
 
Term 
 
Coef 
 
SE Coef 
Constant 0.30833 0.00630 Constant 35.534 0.293 Constant 31.731 0.814 
X1 (pH-pI) 0.05150 0.00386 X1 (pH-pI) 6.405 0.300 X1 (pH-pI) 6.113 0.599 
X2 (SeMet 
(mg/mL)) 
0.00838 0.00386 
X2 (SeMet 
(mg/mL)) - - 
X2 (SeMet 
(mg/mL)) - - 
X3 (Ratio 
of Cs:TPP) 
0.05213 0.00386 
X3 (Ratio of 
Cs:TPP) 1.245 0.300 
X3 (Ratio of 
Cs:TPP) 0.487 0.599 
X1*X1 -0.06129 0.00568 X1*X1 - - X1*X1 3.821 0.879 
X2*X2 0.10396 0.00568 X2*X2 - - X2*X2 - - 
X3*X3 0.06446 0.00568 X3*X3 -2.626 0.419 X3*X3 -3.529 0.879 
X1*X2 -0.01750 0.00545 X1*X2 - - X1*X2 - - 
X1*X3 0.01650 0.00545 X1*X3 - - X1*X3 - - 
X2*X3 -0.04025 0.00545 X2*X3 - - X2*X3 - - 
Lack of fit 0.27 Lack of fit 0.09 Lack of fit 0.62 
R2adjusted 98.66% R2adjusted 98.65% R2adjusted 90.82% 
Eq. (5) 
 
 
Y2 = 0.592 + 0.212 X1 
- 1.565 X2 - 0.1495 X3 - 0.06 
X1*X1 
+ 10.40 X2*X2 +0.01611 
X3*X3 -0.175 X1*X2 +0.00825 
X1*X3 - 0.2012 X2*X3 
Eq. (6) 
 
 
Y3 = -1.21 + 6.405 X1 + 
8.49 X3 - 0.6588 X3*X3 
 
 
 
Eq. (7) 
 
 
Y4 = -2.06 + 5.35 X1 + 
10.83 X3 + 3.821 X1*X1 
- 0.882 X3*X3 
 341 
In table 2 (Eq. 5), PDI was mostly affected by the quadratic effects of X2*X2, which showed 342 
a positive correlation such that, at -1 and +1 levels of X2, the PDI increased. It is also worth 343 
noting that the linear term of X2 showed a negative coefficient, indicating that X2 has a 344 
negative effect on PDI until a turning point is reached, whereafter X2*X2 has a positive 345 
impact on PDI. Similar findings were reported by Masarudin et al., (2015), who found that 346 
ratios of Cs:TPP less than 3:1 and greater than 12:1, resulted in a significant increase of the 347 
formed NPs PDI values (>0.75). Additionally, they found that the NPs produced at ratios 348 
between (median levels) the aformentioned upper and lower bounds resulted in NPs with PDI 349 
values ranging from 0.15-0.32.  A contour plot based on the regression model is presented in 350 
Figure 1(A) and highlights this, showing that, at medium load concentrations of 0.15 mg/mL 351 
and medium/low ratios of Cs:TPP (4.75:1 to 5.5:1), a minimum value for PDI can be 352 
achieved. Conversely, as the concentration of TPP passes median levels PDI increases, which 353 
may be attributable to TPP inducing cross-linking between the nanoparticles and thus the 354 
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presence of smaller aggregates within the solution (Antoniou et al., 2015a; Hu et al., 2008). 355 
Furthermore, the reduction of PDI as the concentration of TPP approaches median levels, has 356 
been shown to relate with the increased availability of TPP molecules to interact with the free 357 
amino groups of chitosan, thus allowing for additional incorporation of the anion within the 358 
nanoparticle chitosan chains  (Huang and Lapitsky, 2017). Although PDI can be minimised at 359 
these particular levels, it is worth noting that the PDI values for all formulations fell within 360 
optimum values for oral delivery (Wong et al., 2017). 361 
 362 
The results presented in table 2 (Eq.6) show that ZP was not affected by X2, although it was 363 
affected by X1 (pH-pI) and X3 (Cs:TPP), indicating that the pH of the formulation medium 364 
and the electrostatic forces between the ionizable groups of Cs and TPP determine the net 365 
charge of the produced particles. It is likely that this is a direct consequence of the binding 366 
between the anionic phosphate groups of TPP with the positively charged amino acid 367 
moieties of Cs (Rampino et al., 2013), for example, a positive correlation was observed, such 368 
that ZP increased with increasing ratios. In addition, X1 also showed a prominent effect on 369 
ZP, whereby an increase in ZP is observed as X1 increases. The contour plot representing the 370 
reduced regression model (Figure 1(B)), demonstrates that low X1 levels (pH 5 - 4.2) and low 371 
ratios of Cs:TPP (4.0/4.5:1) are the areas where NPs of ZP <30mV were obtained (with a 372 
minimum of 27 mV). As X1 increases (approximately pH 3.5), an increment in ZP was 373 
observed and maximum values of >39 mV are achieved between X3 (ratio) of 4.5:1 - 7.5:1. 374 
This is in agreement with previous studies by Antoniou et al., (2015), that showed at Cs: TPP 375 
mass ratios of 7:1, the ZP of the produced NPs decreased almost linearly with increasing pH 376 
of the formulation medium. As it has been shown that high ZP (either negative or positive), 377 
requires higher energy for bringing two particles in contact with each other (Dora et al., 378 
2010), this pH-responsive behaviour can be attributed to the protonation of the primary amino 379 
18 
 
groups present on the Cs chain, resulting in an increase of electron density and repulsion 380 
forces between the crosslinked Cs chains (Lai and Guo, 2011). For example, at pH 3.5, the 381 
charge interaction between these two molecules becomes strong enough, and stable Cs NPs 382 
are obtained. On the contrary, at pH approaching the pI of Cs, reduced availability of 383 
protonated amine residues (-NH3+) present on the Cs polymer backbone chain results in a 384 
lower surface charge of the formed NPs (Huang et al., 2015). 385 
 386 
EE% was not affected by load concentration (X2) but was mostly affected by the pH of the Cs 387 
media (pH-pI (X1)) (table 2 (Eq.7)), demonstrating the notable effect of SeMet loading with 388 
the charge of both polyelectrolytes (Cs and TPP) and their subsequent interaction during the 389 
crosslinking process. As can be seen, a negative correlation was observed, indicating that, as 390 
X1 increases, the EE% decreases, most likely attributable to the reduced protonation of the 391 
primary amines present on Cs (Umerska et al., 2014). It is also worth noting that the 392 
quadratic term X1*X1 showed a positive coefficient, indicating X1 had a negative effect on 393 
EE% until a turning point was reached, where after X1 had a positive impact on EE%. He et 394 
al., (2017), reported that by exploiting the ionic nature of insulin through modulation of the 395 
formulation media, the EE% of insulin into Cs:TPP NPs could be significantly enhanced, 396 
going from 37 to 94 %. This is evident in the contour plot produced by the regression model 397 
(Figure 1(C)) showing that, at maximum X1 levels (approximately 2.5 unit distance from pI 398 
of SeMet) and minimum to median/high ratios of Cs:TPP (4:1 - 7.5:1), maximum EE % (>40 399 
%) can be achieved, indicating that pH plays a significant role in the EE%. These findings 400 
agree with those of other research groups (Antoniou et al., 2015b; Janes et al., 2001), that 401 
reported a strategy to increase ionisable proteins (such as bovine serum albumin (BSA)  and 402 
insulin) EE% (>80%) within a Cs NP matrix, by dissolving the load protein at a pH above its 403 
isoelectric point. By doing this, deprotonation of the hydroxy groups present on the load 404 
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cargo occurs, inducing a predominantly negative state and thus has a higher affinity to Cs and 405 
increased EE%. Several other studies have mirrored these findings, showing that the 406 
electrostatic interactions between the acidic groups present on insulin and the amino groups 407 
of Cs play a role in the association of insulin to the Cs-NPs by mediation of the ionic 408 
interaction between both macromolecules (Mattu et al., 2013; Pan et al., 2002).  409 
 410 
Figure 1: Contour Plot of (A) PDI against ratio of Cs:TPP (X3) and SeMet (mg/mL) 411 
(X2), with pH-pI (X1) held at median level (1.5), (B) ZP against pH-pI (X1) and the ratio 412 
of Cs:TPP (X3) and (C) EE% against pH-pI (X1) vs ratio of Cs:TPP (X3) for the RSM 413 
models presented in Table 2. 414 
3.2 Optimisation 415 
Employing the models constructed with the BBD evaluation in Table 2, response 416 
optimisation was employed in order to establish a formulation strategy to yield NPs with 417 
minimum PDI values, ZP of ≥30 mV and maximum EE% (des Rieux et al., 2006). As the 418 
range of NP sizes within all experimental runs fell within recommended target values for oral 419 
delivery, this response was excluded from the optimisation analysis.  420 
 421 
Figure 2 shows the optimisation plot of the desired responses and indicates that, when the 422 
variable settings of X1, X2 and X3 are fixed at 2.5 (pH-pI), 0.15 (mg/mL) and 6 (Cs:TPP), 423 
respectively, NPs with the desired properties can be produced. Additionally, the 95 % 424 
confidence interval ranges of the predicted NP properties that these conditions would produce 425 
are presented in Table 3. 426 
 427 
Figure 2: Desirability profiles for optimisation of the formulation parameters; X1 (pH-428 
pI), X2 (load concentration) and X3 (Ratio of Cs:TPP) - maximising ZP and EE%, 429 
whilst minimising PDI. 430 
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Table 3: 95% confidence interval for particle characteristics that optimal conditions 431 
would produce under the present experimental conditions of uncertainty 432 
Response Fit  95 % CI Actual values 
Y2 (PDI) 0.299 ± 0.007 (0.282, 0.317) 0.284 ± 0.044 
Y3 (mV) 42.2 ± 2.0 (41.6, 42.7) 39.7 ± 2.6 
Y4 (EE%) 41.7 ± 1.0 (39.5, 43.8) 39 ± 3 
 433 
To verify the validity of the proposed models, n = 4 replicates of the optimised formulation 434 
were prepared, and each experimental response was compared with the predicted one. Table 435 
3 shows the validation results of the model, whereby NPs presented sizes of 187 ± 58 nm, 436 
PDI of 0.284 ± 0.044, ZP of 39.7 ± 2.6 mV and a max EE % of 39 ± 3 %. No statistical 437 
significant values (p>0.05) for predicted and measured responses (Y2-Y4) were observed, 438 
indicating that the models fit the data satisfactorily and has adequate precision for the 439 
prediction of NP ZP, PDI and EE% in the chosen space of independent variables (in the 440 
domain of levels chosen for the independent variables). Additionally, several consuming and 441 
laborious laboratory studies were eliminated in this study by using the BBD, rather than a 442 
OFAT approach. 443 
3.3 EE% optimisation I: protonation and ionisation 444 
The results from the BBD were promising in terms of the NPs produced and their 445 
physicochemical properties. However, even when optimised, EE% remained low at 446 
approximately 40 %. A second study was undertaken with the aim of maximising the EE%, 447 
by controlling the ionisation process, given that this property primarily influenced the 448 
encapsulation efficiency in the desirability profile (Figure 2). In the previous BBD, it was 449 
noted that the highest EE% of SeMet within Cs:TPP NPs was obtained when the pH of the Cs 450 
medium was maintained at pH 3 and the SeMet load was dissolved within it prior to 451 
crosslinking. The fundamentals of ionotropic gelation exploit the opposing charges between 452 
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the protonated amine residues found on the glucosamine residue unit of Cs against the 453 
deprotonated hydroxyl groups on TPP (Janes et al., 2001). In order to increase the EE%, a 454 
modulation of the ionisation state of SeMet was achieved by dissolving it (and TPP) in a 455 
basic solution prior to crosslinking with Cs. The rationale for this approach is the observation 456 
that the pKa for the acid moiety of SeMet is pH 2.6, whereas the pKa for the basic moiety is 457 
at pH 8.9 (Foulkes, 2003) and as such, further electrostatic interactions can be induced at time 458 
of complexation (Qi et al., 2010). The effect of dissolving the TPP and SeMet in 0.01 M 459 
NaOH (pH 12) rather than H2O prior to crosslinking in the optimised formulation (ratio 460 
Cs:TPP 6:1, SeMet load concentration of 0.15 mg/mL and Cs medium pH of 3) was 461 
investigated, as a means to elicit greater interaction between Cs and SeMet and subsequently 462 
increase EE%. N= 3. 463 
 464 
By altering the pH of the formulation, the EE% increased from 39 ± 3 % to 66 ± 1 %, whilst 465 
the physicochemical properties of the NPs remained within the target range for oral delivery 466 
(Table 4) (des Rieux et al., 2006). This was most likely attributed to the electrostatic 467 
interactions between the now further ionised TPP and SeMet groups and protonated amine 468 
residues found on the glucosamine unit of Cs. This is consistent with the work by Pan et al., 469 
(2014) which showed curcumin (CUR) successful encapsulation (>90%) into casein NPs, 470 
through deprotonation of CUR at pH 12, enabling for its re-association and thus subsequent 471 
encapsulation into the NP matrix. 472 
 473 
 474 
3.4 Improved Encapsulation Efficiency using zein  475 
The results from the first EE% optimisation study (Table 4) were promising, in terms of 476 
increasing EE% in addition to maintaining the desired NP physicochemical properties. 477 
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Nevertheless, the maximum EE% obtained by modifying the pH remained at 66 ± 4 %. 478 
Therefore, a subsequent step, involving the coating of the optimised NPs with zein (at 479 
varying zein:Cs mass ratios), was pursued as a means to increase the encapsulation efficiency 480 
of SeMet into the Cs: TPP NPs.   481 
 482 
As shown in Table 4, as the ratio of zein in the formulation increased, the EE% improved. At 483 
0.5:1, zein:Cs, the average EE% achieved was 75 % and approximately 5 % increments in 484 
EE% were observed with subsequent increments of zein:Cs. The physicochemical properties 485 
of the NPs (PDI and ZP) were still within the target range for oral delivery for formulations 486 
with zein:Cs ratios ≤1:1, although an increase in NP size was observed upon increasing zein 487 
concentrations. At a ratio of 2:1, zein:Cs, the physicochemical properties of the NPs were less 488 
than ideal, as large particle sizes (721 nm average) and high PDI values (0.783) were yielded, 489 
most likely as a consequence of a denser and thicker coating (Luo et al., 2010) provided by 490 
the partial deposition of the negatively charged protein on the particle surface, thus reducing 491 
the total net charge and inducing particle swelling (Rampino et al., 2013). For example, as the 492 
zein concentration increases, so does the viscosity of the dispersion, which can affect the 493 
nucleation process leading to the production of larger sized NPs (Zhong and Jin, 2009).  494 
Similar results have been observed by others, whereby, an increase in zein concentration led 495 
to an increase in particle size of 6,7-dihydroxycoumarin loaded zein NPs (Podaralla and 496 
Perumal, 2012) or alpha-tocopherol loaded zein NPs, stabilised with Cs (Luo et al., 2012). 497 
Lastly, the ZP of this formulation was the lowest observed (average of + 6 mV), which may 498 
be attributed to the increasing zein concentration, causing increased masking of the free 499 
positively charged amino groups of Cs (Krauland and Alonso, 2007). It is also possible that 500 
agglomeration occurred as a result of the reduced electrostatic repulsion between the NPs in 501 
suspension (Liu and Gao, 2009). 502 
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 503 
Table 4: Physiochemical results for SeMet loaded NPs (Ratio 6:1, SeMet in NaOH (0.15 504 
mg/mL load), Cs in pH 3) coated with zein. Size, PDI, ZP and EE% are presented for 505 
each NP using different mass ratio combinations of zein and Cs. N=3. 506 
Zein:Cs Size (nm) PDI ZP (mV) EE (%) 
0:1 227 ± 17 0.448 ± 0.049 32 ± 1 66 ± 4 
0.5:1 319 ± 19 0.221 ± 0.040 27 ± 6 74 ± 1 
1:1 377 ± 47 0.325 ± 0.136 35 ± 6 81 ± 1 
2:1 721 ± 108 0.783 ± 0.281 6 ± 4 85 ± 1 
 507 
3.5 Characterisation of SeMet loaded and unloaded Cs:TPP NPs with and without 508 
zein coating - Fourier transform infrared spectroscopy (FTIR) 509 
Figure 3 shows the FTIR spectra of (A) zein, (B) TPP, (C) Cs, (D) SeMet:Cs:TPP NPs and 510 
(E) SeMet:Cs:TPP:zein NPs. The zein spectrum (Figure 3, A) shows characteristic peaks at 511 
3289, 2929, 1644, 1515 and 1233 cm-1 corresponding to; NH stretching vibrations, CH 512 
stretching, amide I (C=O stretch), amide II (C-N and C-N-H/ in plane bending) and amide III 513 
respectively (Podaralla and Perumal, 2012). Characteristic peaks for the phosphate ion (P=O) 514 
in TPP (Figure 3, B) were observed at 1121 cm-1 and 886 cm-1, respectively (Rampino et al., 515 
2013). Cs spectra (Figure 3, C) showed characteristic peaks at 3240, 2879, 1625, 1514, 1376 516 
and 1063 cm-1. corresponding to NH Stretch / OH in pyranose ring, CH2 in CH2OH group, 517 
C=O in NHCOCH3 group (amide I), NH2 in NHCOCH3 group (amide II), CH3 in NHCOCH3 518 
group and C-O-C (glycosidic linkage) respectively (Luo et al., 2010; Mohammed et al., 519 
2013). 520 
 521 
Figure 3: FTIR spectra of (A) zein, (B) TPP, (C) Cs, (D) SeMet:Cs:TPP NPs and (E) 522 
SeMet:Cs:TPP:zein NPs. Spectra are offset for clarity. 523 
 524 
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The FTIR spectrum of SeMet:Cs:TPP NPs (Figure 3, D) is different to that of the Cs matrix, 525 
as a result of intermolecular interactions of the constituent components. If interaction 526 
between the Cs and TPP had occurred, it will lead to frequency shifts or splitting in 527 
absorption peaks (Gan et al., 2005).  For example, the peaks at 1514 cm-1 in the Cs spectrum 528 
have been shifted to 1560 cm-1, indicating electrostatic interaction between the phosphate 529 
groups of TPP and the amino groups present in the Cs NP matrix (Papadimitriou et al., 2008). 530 
Additionally, the broadening and the increased absorbance of the peak at 3272 cm-1 indicate 531 
hydrogen bonding has been enhanced (Luo et al., 2010). The band observed at 1644 cm−1 in 532 
the zein FTIR spectrum (assigned to N-H bond), has been shifted to 1648 cm−1 in the zein/Cs 533 
NPs spectrum (Figure 3, A and E respectively), indicating an interaction among the zein and 534 
Cs chains, possibly through hydrogen bonding among the amino groups present on both Cs 535 
and zein chains (Müller et al., 2011). Another indication of Cs:zein interaction arises from the 536 
amide III bands at 1406 cm-1, not visible in the zein spectrum, but now visible in the zein/Cs 537 
NPs (Figure 3, A and E respectively) spectrum, most likely as a result of the C-N stretching 538 
and out of plane N-H deformation being highly sensitive to structural changes (Sessa et al., 539 
2008). 540 
 541 
Lastly, the formation of zein/Cs NPs (E) is also characterised by the appearance of a band at 542 
1041 cm−1 (assigned to C-O-C (glycosidic linkage)), which was observed in Cs/SeMet NPs 543 
(D) at 1028 cm−1 but not observed in the zein spectrum (A), supporting the presence of Cs 544 
within the NP matrix (Figure 3) (Müller et al., 2011). The crosslinked Cs also showed a peak 545 
for P = O at 1151 cm–1 (Bhumkar and Pokharkar, 2006), further indicating electrostatic 546 
interaction between Cs and TPP (Figure 3, E). No significant SeMet peaks in either 547 
Cs/TPP/SeMet or Cs/TPP/SeMet/zein NPs spectra were observed, most likely due to the fact, 548 
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that only 0.07 % of the dried formulation is contributed by SeMet and it is consequently 549 
masked by the other formulation components. 550 
3.6 Scanning electron microscopy  551 
Figure 4 shows the SEM images of uncoated and zein coated Se loaded NPs. The particle size 552 
of the NPs after spin coating was in good agreement with the DLS measurements taken on 553 
the freshly prepared NPs. Spherical, well distributed particles for both coated and uncoated 554 
SeMet loaded NPs were observed. However, it is interesting to note that the zein coated NPs 555 
displayed a smoother surface than that of the uncoated. This may be attributed to the use of 556 
the acetic acid buffer used during the formulation process, as similar results have been 557 
observed in spin-cast zein films prepared from an aqueous ethanol solvent compared to an 558 
acetic acid solution, indicating that a rough and hydrophilic surface was acquired for the 559 
former, whilst the zein film produced from an acetic acid solution appeared to be smooth, 560 
featureless and more hydrophobic (Shi et al., 2009; Y. Zhang et al., 2015).  561 
 562 
Figure 4: SEM image of (A) SeMet:Cs:TPP NPs and (B) SeMet:Cs:TPP NPs coated 563 
with zein 564 
3.7 Accelerated stability analysis of SeMet-loaded NPs coated with zein 565 
The principle aim of accelerated stability testing is to provide reasonable assurance that a 566 
pharmaceutical or food consumable will remain at an acceptable level of quality throughout 567 
its timespan in the market place (Bajaj et al., 2012; Waterman and Adami, 2005). Real-time, 568 
retained sample, cyclic temperature and acceleration, are the four categories into which 569 
stability testing procedures fall (Bhagyashree et al., 2015). In the latter, the product is 570 
subjected to elevated temperatures and/or humidity well above ambient values, to determine 571 
the temperature at which product failure (i.e. degradation) will occur. 572 
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 573 
The Arrhenius equation, upon which the interpretation of accelerated stability testing is 574 
based, allows for the determination of the activation energy and consequently, the 575 
degradation rate of a product at lower temperatures (i.e. ambient, refrigerated etc.). In this 576 
instance, the data acquired can then be used to project the shelf life of the product in a much 577 
shorter time than that of real time assessments (Ali et al., 2013; Bhagyashree et al., 2015). 578 
This is a beneficial approach to stability testing, as it results in a greatly reduced product 579 
development schedule.  580 
Figure 5 shows the kinetic behaviour of the NP properties; size (A), PDI (B) and ZP (C) at 581 
temperatures ranging from 60-80 °C. The stability of the NPs decreased with increasing 582 
temperature. Little change was detected for all properties at 60 °C, over the course of 720 583 
min, whereas a more pronounced increment in size and PDI and a decrease in ZP was 584 
observed at 70 °C after 300 min. At 80 °C, destabilisation of the NP complexes was evident 585 
across all properties, whereby size increased from approximately 300 nm to > 800 nm, PDI 586 
from approximately 0.2 to >0.9 and ZP reduced from approximately 32 mV to < 18 mV, 587 
indicating that aggregation of the NPs had occurred (Wu et al., 2011). 588 
 589 
Figure 5: (1) Particle size, (2) PDI and (3) ZP analysis of SeMet loaded NPs exposed to 590 
(a) 80 °C, (b) 70 °C and (c) 60 °C, over time periods of 120, 300 and 720 min, 591 
respectively. N=3 592 
The one-step nonlinear regression analysis of the kinetic experiments shows that particle size 593 
and PDI fit to a zero-order kinetic behaviour, with an Arrhenius dependence of ln (kref@70 594 
°C) = 1.66 ± 9.44 min−1 and Ea = 452.57 ± 570.59 kJ/mol for size, and a ln (kref@70 °C) = 595 
0.029 ± 0.014 min−1, and an Ea = 182.31 ± 42.64 kJ/mol for PDI respectively. In terms of ZP, 596 
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an apparent first order mechanism fits the data better than that of an apparent zero order 597 
model, with an Arrhenius dependence of ln (kref@70 °C) = 0.038 ± 0.010 min−1 and Ea = 598 
205.71 ± 25.65 kJ/mol. Additionally, as can be seen in figure 6, a linear correlation is evident 599 
between 1/T and ln k, indicating that the formulations will be stable under normal storage 600 
conditions. This was expected, as previous reports have shown that zein coatings can increase 601 
the colloidal stability of iron phosphate NPs (Van Leeuwen et al., 2014) and, when stabilised 602 
with Cs, results in high thermal resistance of the NPs over prolonged periods of time  (Luo et 603 
al., 2013). 604 
 605 
Figure 6: Arrhenius plots for the (A) ZP, (B) PDI and (C) size accelerated studies of 606 
SeMet loaded NPs. N=3. 607 
3.8 Cytotoxicity assessment of SeMet-loaded NPs 608 
The potential cytotoxicity of SeMet in its native form and unloaded or SeMet loaded NPs 609 
coated with zein, at different test concentrations (25, 50 and 100 uM), were examined on 610 
Caco-2 human epithelial cells, and HepG2 human liver hepatocellular cells, using the MTS 611 
assay. As the NPs will become exposed to the intestinal epithelia following oral delivery 612 
(leading to its facilitated transport and uptake), time points were selected with the intention to 613 
mimic in vivo conditions for each cell type, to assess the potential cytotoxicity of the 614 
formulated NPs (Gleeson et al., 2015; Brayden et al., 2015). Caco-2 cells were exposed for 615 
4h (figure 7(A)) and HepG2 cells for 72h (figure 7(B)). In Caco-2 exposures, no cytotoxicity 616 
was observed for unloaded or SeMet loaded NPs, in comparison to the negative control, 617 
across all tested concentrations. For HepG2 exposures, no cytotoxicity was observed for 618 
unloaded or SeMet loaded NPs coated with zein. Additionally, the lower concentrations (25 619 
and 50 uM) of native SeMet showed no cytotoxicity to either cell line, whereas a reduction in 620 
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HepG2 cell viability (figure 7(B)) for native SeMet, at the 100 μM test concentration, was 621 
observed (approx. 66% cell viability).  622 
 623 
Similar results were observed by Takahashi, Suzuki and Ogra, 2017, whereby SeMet showed 624 
no significant change on the viability of Caco-2 cell lines, although it did show marginal 625 
toxicity to HepG2 cells at concentrations > 80 ug/mL after prolonged exposure (48 hr). This 626 
finding is also in agreement with other works that showed SeMet toxicity occurred at 627 
concentrations ≥40 uM in various hepatoma cell lines (Kajander et al., 1991). It has 628 
previously been shown that Cs nanoparticles can enhance the delivery of inorganic Se 629 
compounds whilst reducing its toxicity (C. Zhang et al., 2015). In this work, SeMet loaded 630 
NPs elicited no significant reduction in viability of either cell line at equivalent concentration 631 
(100 uM), indicating that, by encapsulating SeMet within the Cs NP matrix, the cytotoxic 632 
effects of pure SeMet, can be reduced.  633 
 634 
Figure 7: Cytotoxicity assessment of  SeMet,  unloaded NPs with zein coating and 635 
 SeMet loaded NPs with zein coating, exposed for (a) 4h in Caco-2 cell lines and (b) 72h 636 
in HepG2 cell line at SeMet equivalent concentrations (25 uM, 50 uM and 100 uM). Triton™ 637 
X-100 (0.05%) was used as positive control and percentage (%) of MTS converted was 638 
compared to untreated control. 1-Way ANOVA with Dunnetts’s post-test *** P< 0.001, ** 639 
P< 0.01, Each value presented was normalised against untreated control and calculated from 640 
three separate experiments, each of which included six replicates. N=3 641 
 642 
 643 
3.9 In vitro release studies 644 
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In vitro techniques are advantageous for modelling potential interactions between NPs and 645 
the in vivo environment of the GI tract. Simulated gastric fluid and membrane analysis 646 
models enable assessment of in vivo environments without the use of human cell lines 647 
(Gamboa and Leong, 2013). Figure 8, shows the cumulative release profile of SeMet loaded 648 
NPs coated with zein, after subjection to 2 hr in an SGF environment (pH 1.2) representative 649 
of the stomach, followed by a compartmental change to SIF (pH 6.8), representative of the 650 
intestine, for 4 hr. As can be seen, 25±1 % of SeMet was released after 2 hr in SGF, followed 651 
by 33 ±3 % in SIF for 4 hr. No significant difference in the release profile of SeMet loaded 652 
NPs without zein coating was observed (data not shown). However, it was necessary to keep 653 
zein in the formulation due to the increase in EE (≥ 80 %). 654 
 655 
The target site of absorption of SeMet is the jejunum, in the small intestine. Therefore, it is 656 
important to withstand the acidic environment of the stomach. Three basic mechanisms that 657 
are typically applied to describe the release of drugs from polymeric particles, are 658 
swelling/erosion, diffusion, and degradation (Liechty et al., 2010). In this work, the total 659 
cumulative release of SeMet from the zein coated NPs, after 6 hr in simulated gastrointestinal 660 
tract environments, was 58 %, indicating that degradation of the NP was slow and thus the 661 
mechanism may be diffusion/relaxation oriented. As such, the release kinetics of SeMet NPs, 662 
under the SGF and SIF sequential controlled release experiments, were fitted using the 663 
following diffusive models derived from swellable systems (Siepmann and Peppas, 2011; 664 
Danish et al., 2017a). 665 
 666 
 667 
 668 
For the SGF: 669 
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𝑀𝑡
𝑀∞
= 𝑘𝑠1 ∗ (√𝑡𝑡𝑡𝑡) + 𝑘𝑠2 ∗ 𝑡𝑡𝑡𝑡       670 
       (Eq.8) 671 
where 𝑀𝑡 is the diffused mass at a given time, 𝑀∞ is the asymptotic diffused mass at infinite 672 
time, and ks1 and ks2 are the diffusive and relaxation rate constants respectively. 673 
 674 
For the SIF: 675 
 676 
𝑀𝑡
𝑀∞
−
𝑀120
𝑀∞
= 𝑘𝑡1 ∗ (√𝑡𝑡𝑡𝑡 − 120) + 𝑘𝑡2 ∗ (𝑡𝑡𝑡𝑡 − 120)     677 
          (Eq.9) 678 
where M120 is the predicted diffused mass at the time of changing from SGF to SIF (120 679 
min), ki1 and ki2 are diffusive and relaxation rate constants. 680 
 681 
Table 5: Swellable model parameters for kinetic release studies SeMet NPs. ks 682 
represents the stomach compartment and ki the intestinal compartment, divided into 683 
diffusion and relaxation mechanisms (1 and 2). All parameters listed where statistically 684 
significant, ∗∗∗P < 0.001; ∗P < 0.05. 685 
Parameters Estimate Std. Error t-value Significance code 
Ks2 0.17082 0.04092 4.175 *** 
Ki1 0.69145 0.33863 2.042 * 
Ki2 0.10817 0.02105 5.140 *** 
R2adj 0.984 
 686 
Table 5 presents the fitted values for the rate constants in SGF (ks) and SIF (ki) for SeMet 687 
NPs, with ks1, representing a diffusion mechanism and ks2 a relaxation mechanism (Eq. 8, 9). 688 
In terms of the stomach compartment (SGF, pH 1.2), no statistically significant ks1 parameter 689 
was found, indicating that the primary mechanism for release in the stomach was via 690 
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relaxation, i.e. slower release, approaching zero-order kinetics. After 2 hr subjected to the 691 
SGF environment, a compartmental change was employed to mimic the movement of the 692 
NPs to the intestinal environment (SIF, pH 6.8), whereupon a combination of diffusion (ki1) 693 
and relaxation (ki2) mechanisms were observed (p<0.05). Overall, the model employed (Eq. 694 
8, 9) predicted the experimental data well, with an R2adj >0.98. These results were expected, 695 
as polysaccharides generally undergo solvent penetration, swelling and chain 696 
disentanglement and relaxation, resulting in their ultimate dissolution (Fu and Kao, 2010). 697 
Additionally, this result is in agreement with previous studies, reporting a diffusion and zero 698 
order kinetic profile for IPP and LKP loaded CsNPs, coated with zein (Danish et al., 2017a) 699 
and that of other researchers, who observed that zein proved to be a good coating for NPs, 700 
whereby, the stronger the interaction of the load material (in this instance phenolic 701 
monoterpenes) with that of the wall material (zein) was evidenced by its controlled release 702 
over time (da Rosa et al., 2015). 703 
 704 
Figure 8: Release kinetics of SeMet NPs coated with zein after 2 hr in SGF (pH 1.2) and 705 
4 hr in SIF (pH 6.8).  706 
 707 
4 CONCLUSION 708 
In this study, SeMet-loaded Cs NPs were produced via ionotropic gelation. BBD was used to 709 
identify optimum formulation variables that would result in NPs with physicochemical 710 
properties thought to be suitable for oral delivery. BBD highlighted the optimum conditions 711 
for NP production, although EE% remained relatively low. By varying the formulation media 712 
pH, increased electrostatic interaction between the crosslinking polyelectrolytes and drug 713 
were achieved, resulting in an increase in EE %. Coating the NPs at a 1:1 mass ratio of 714 
Cs:zein, resulted in NPs with a doubled EE accompanied by an increase in diameter. These 715 
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NPs were then characterised via FTIR analysis, which identified the presence of key 716 
functional groups of the native components and identifying shifts in the crosslinked matrixes. 717 
SEM analysis showed that spherical, well distributed particles were observed. MTS 718 
cytotoxicity studies showed no decrease in cellular viability in either Caco-2 or HepG2 cell 719 
after 4 and 72 hr exposures, respectively. Accelerated thermal stability of the loaded NPs 720 
indicated good stability under normal storage conditions. Lastly, after 6 hr exposure to 721 
simulated intestinal buffers, the release profile of the formulation showed that ≤ 60% of the 722 
drug had been released. These findings infer that encapsulation of SeMet into a NP delivery 723 
system comprising food-derived components reveals an oral administration approach for this 724 
molecule. 725 
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 1056 
The above graphic depicts the formulation methodology used to produce selenomethionine 1057 
loaded chitosan nanoparticles, coated with zein, for in vitro assessment. Briefly, to produce 1058 
the nanoparticles, chitosan was protonated by dissolving in acidic buffer (pH 3), then 1059 
crosslinked with ionised tripolyphosphate and selenomethionine in NaOH (0.1 M). Zein 1060 
coating was then employed to coat the nanoparticles and purification was achieved by 1061 
removing unencapsulated formulation components through ultracentrifugation. 1062 
 1063 
Figure 1: Contour Plot of (A) PDI against ratio of Cs:TPP (X3) and SeMet (mg/mL) 1064 
(X2), with pH-pI (X1) held at median level (1.5), (B) ZP against pH-pI (X1) and the ratio 1065 
47 
 
of Cs:TPP (X3) and (C) EE% against pH-pI (X1) vs ratio of Cs:TPP (X3) for the RSM 1066 
models presented in Table 2. 1067 
 1068 
Figure 2: Desirability profiles for optimisation of the formulation parameters; X1 (pH-1069 
pI), X2 (load concentration) and X3 (Ratio of Cs:TPP) - maximising ZP and EE%, 1070 
whilst minimising PDI. 1071 
 1072 
Figure 3: FTIR spectra of (A) zein, (B) TPP, (C) Cs, (D) SeMet:Cs:TPP NPs and (E) 1073 
SeMet:Cs:TPP:zein NPs. Spectra are offset for clarity. 1074 
 1075 
Figure 4: SEM image of (A) SeMet:Cs:TPP NPs and (B) SeMet:Cs:TPP NPs coated 1076 
with zein 1077 
 1078 
Figure 5: (1) Particle size, (2) PDI and (3) ZP analysis of SeMet loaded NPs exposed to 1079 
(a) 80 °C, (b) 70 °C and (c) 60 °C, over time periods of 120, 300 and 720 min, 1080 
respectively. N=3 1081 
Figure 6: Arrhenius plots for the (A) ZP, (B) PDI and (C) size accelerated studies of 1082 
SeMet loaded NPs. N=3. 1083 
 1084 
Figure 7: Cytotoxicity assessment of  SeMet,  unloaded NPs with zein coating and 1085 
 SeMet loaded NPs with zein coating, exposed for (a) 4h in Caco-2 cell lines and (b) 72h 1086 
in HepG2 cell line at SeMet equivalent concentrations (25 uM, 50 uM and 100 uM). Triton™ 1087 
X-100 (0.05%) was used as positive control and percentage (%) of MTS converted was 1088 
compared to untreated control. 1-Way ANOVA with Dunnetts’s post-test *** P< 0.001, ** 1089 
P< 0.01, Each value presented was normalised against untreated control and calculated from 1090 
three separate experiments, each of which included six replicates. N=3 1091 
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 1092 
Figure 8: Release kinetics of SeMet NPs coated with zein after 2 hr in SGF (pH 1.2) and 1093 
4 hr in SIF (pH 6.8).  1094 
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